论文部分内容阅读
从微量血清中分离纯化的中性糖脂(N-GSL),应用薄层扫描定量法测定的结果表明:原发性肝癌(PHC)病人血清的N-GSL总量(以CMH相应量表示)为44nmol/ml血清,为正常人血清含量的1.51倍。高效薄层层析(HPTLC)分析表明,PHC血清的N-GSL图谱与正常人血清图谱相似,主要成分为CMH、CDH、CTH、Glob和PG。不同的是,PHC血清HPTLC图谱中在CTH和Glob之间出现了一条新的条带,层析证实为去唾液酸的GM_2(As-GM_2),其含量为0.71±0.13nmol/ml血清。As-GM_2在PHC血清中的出现可能提示其为肝癌相关的血清糖脂标记。
The purified neutral glycolipid (N-GSL) was isolated from trace amounts of serum and the results of thin-layer scan quantification showed that the total amount of N-GSL in the serum of patients with primary liver cancer (PHC) was expressed as the corresponding amount of CMH. For 44nmol/ml serum, 1.51 times the normal human serum content. High-performance thin-layer chromatography (HPTLC) analysis showed that the N-GSL profile of PHC serum was similar to that of normal human serum and the main components were CMH, CDH, CTH, Glob, and PG. The difference is that there is a new band between the CTH and Glob in PHC serum HPTLC pattern, and the chromatographic confirmation is sialic acid GM 2 (As-GM 2 ), whose content is 0.71±0.13 nmol/ml serum. The presence of As-GM2 in the serum of PHC may indicate that it is a marker of liver cancer-associated serum glycolipids.